AbbVie Asks High Court To Review Sham Litigation Exception

By Melissa Angell (March 18, 2021, 10:49 PM EDT) -- AbbVie Inc. asked the U.S. Supreme Court on Thursday to review the Third Circuit's ruling that determined the biopharmaceutical company's patent-infringement suit was a sham after it was accused of delaying the generic forms of the testosterone treatment AndroGel through litigation, saying the appellate court's finding conflicts with the high court's precedent....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!